Xanomeline and Trospium Chloride Capsules
CN012-0008
Phase 3 small_molecule completed
Quick answer
Xanomeline and Trospium Chloride Capsules for Schizophrenia is a Phase 3 program (small_molecule) at Bristol-Myers Squibb Australia Pty Ltd with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Bristol-Myers Squibb Australia Pty Ltd
- Indication
- Schizophrenia
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed